Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab +/- Ipilimumab in Cisplatin-Ineligible Muscle Invasive Bladder Cancer
NCT03520491Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2018
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in bladder cancer and urothelial carcinoma (UC) (4 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients who proceed to radical cystectomy and pelvic lymph node dissection (RC-PLND). Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03520491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520491.